You can find our latest news below
The Award is given to the best published paper, as judged by an independent panel of experts, which demonstrates a remarkable scientific work in the field of cardiovascular diseases.
The Award, consisting of a certificate and a sum of 5,000 Euro,
will be presented to the first author, who is responsible for division among co-authors, at the 25th IFCC-EFLM EuroMedLab Congress to be held in Rome from 21 to 25 May 2023.
Pregnancy-associated plasma protein-A (PAPP-A) is a metalloprotease that belongs to the metzincin superfamily of zinc peptidases. Its main substrate is the insulin-like growth factor binding protein-4 (IGFBP-4). This cleavage causes the release of bound IGF, which plays an important role in promoting cell differentiation and proliferation. PAPP-A was first identified in the serum of pregnant women, hence its name. It was later shown to be expressed in multiple tissues.
We will be participating the 2022 AACC Annual Meeting & Clinical Lab Expo. The exhibition will be on July 26 - 28 in Chicago.
Human C-reactive protein (CRP) is one of the so-called acute phase proteins. CRP is produced in liver and its concentration in blood increases rapidly after a single systemic stimulus and the serum concentrations rise quickly.
We warmly congratulate Dr. Jorge Díaz-Garzón, winner of the third EFLM-HyTest Cardiac Marker award, who finally received his award at the IFCC-EFLM European Congress - EuroMedLab!
Neurofilaments are the main cytoskeletal structure proteins in neurons. They are about 10 nm in diameter, thicker than actin and thinner than myosin, and are thus classed as intermediate filaments (IFs). Neurofilaments comprise four different subunits, the stoichiometry of which varies depending on the maturity of the neuron.
HyTest sponsored SensUs in 2017 when the target molecule was NT-proBNP. In 2022 the aim is to make biosensors for measuring acute inflammation focusing on sepsis. Target molecule is interleukin-6 and we will again sponsor SensUs teams by providing IL-6 antibodies and antigens to them.
The escalation of the conflict between Russia and Ukraine last week has led to a crisis in Europe.
We are following the situation closely and give all our sympathies to the victims and the people affected by the war.
Acute myocardial infarction (AMI) causes damage of heart muscle and the release of troponin complexes in patients’ blood where it can be detected by measuring its components. Early diagnosis of AMI and other myocardial injury associated diseases related to cardiac muscle injury are important for immediate evidence-based therapy. Cardiac troponins I and T (cTnI and cTnT) are currently widely used as a recommended marker of AMI, other myocardial injury associated with postoperative myocardium trauma and many other diseases related to cardiac muscle injury diagnostics. The cTnI has been a gold standard and diagnostic cornerstone in the clinical assessment of AMI as it offers accurate and rapid diagnostics rule out.
HyTest offers a new recombinant cardiac troponin binary complex (rec. cTn IC complex, Cat.# 8ICR3). The new complex is constructed from recombinant cTnI, and TnC isoforms. Resulting complex separated from free recombinant cTnI and TnC isoforms.
We wish you a wonderful holiday season and a happy new year 2022!
This year, we decided to donate our Christmas present funds to lonely elderly and gave a gift of companionship:
Our scientist has discovered new pairs for D-dimer immunoassay development for both chemiluminescence and lateral flow platforms.
We will be attending Medlab Middle East 2022 in the end of January.
Acute myocardial infarction (AMI) causes heart muscle damage and the release of troponin complex that can be detected in patients' blood by the measurement of its components. Cardiac troponin I (cTnI) and cardiac troponin T (cTnT).
Procalcitonin (PCT) is the main marker of disorders that are accompanied by sepsis. The PCT levels in blood are elevated during the systemic inflammation. In addition, the concentration of PCT closely correlates with the severity of inflammation, which further supports the diagnostic value of the marker. While in normal conditions the amount of non-cleaved PCT in blood is low, it increases during systemic inflammation and sepsis.
We will be attending Medica 2021 in November.
The winner of the third EFLM-HyTest Cardiac Marker award will be announced by the EFLM President during the Opening Ceremony of the 24rd IFCC-EFLM European Congress - EuroMedLab in Munich.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (“Mindray”) (300760.SZ), a leading global provider of medical devices and solutions, has completed its previously announced acquisition of HyTest Invest Oy and its subsidiaries (“HyTest”), a global leading provider of antibodies and antigens.
The loneliness of elderly people is a problem in Finland, the homecountry of HyTest. We wanted to be a part of the solution. That is why HyTest is now collaborating with a Finnish company called Gubbe.